GlassScriptPhysician profile
Mazen Sabbaq
NPI 1457318545
$1,554.91
in general payments reported to CMS, 2019-2025
23 companies · $312 in 2025
The $312 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2020: $53.63 · 2021: $75.69 · 2022: $204 · 2023: $744 · 2024: $59.82 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,115.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $319.16 | 2023 | Inspire |
| Glaxosmithkline, LLC. | $262.63 | 2019-2025 | Nucala, Trelegy Ellipta |
| Pulmonx Corporation | $158.35 | 2023-2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Ethicon INC. | $145.89 | 2023 | Monarch Platform |
| Resmed Corp | $81.65 | 2024-2025 | |
| Sunovion Pharmaceuticals INC. | $68.53 | 2019-2020 | |
| Abbvie INC. | $54.16 | 2022-2023 | Avycaz |
| Takeda Pharmaceuticals U.S.A., INC. | $53.14 | 2022-2023 | Hyqvia |
| United Therapeutics Corporation | $45.29 | 2022-2023 | Tyvaso |
| Actelion Pharmaceuticals US, INC. | $44.93 | 2025 | Uptravi, Opsumit, Opsynvi |
| Novartis Pharmaceuticals Corporation | $43.94 | 2019 | |
| Insmed, INC. | $38.49 | 2025 | Arikayce |
| Jazz Pharmaceuticals INC. | $38.47 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $36.16 | 2023 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $35.20 | 2025 | Airsupra, Tezspire |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $25.57 | 2025 | Prolastin-C Liquid |
| Axsome Therapeutics, INC. | $19.42 | 2025 | Sunosi |
| Pfizer INC. | $15.08 | 2022 | |
| Viatris Specialty LLC | $14.78 | 2025 | Yupelri |
| Penumbra, INC. | $14.65 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.80 | 2022 | |
| Inogen, INC. | $12.95 | 2022 | |
| Mylan Specialty L.P. | $12.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mazen Sabbaq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.